US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

6.89

-0.3200-4.44%

Volume:527.82K

Turnover:3.72M

Market Cap:250.05M

PE:-2.64

High:7.28

Open:7.18

Low:6.88

Close:7.21

52wk High:33.20

52wk Low:6.88

Shares:36.29M

Float Shares:19.98M

Volume Ratio:1.23

T/O Rate:2.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:0.90

PE(LYR):-0.61

Loading ...

Overview Company News Filings

Evommune Inc : Leerink Partners Cuts Target Price to $28 from $52

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)

Evommune Sinks as Skin Disease Drug Fails Mid-stage Trial

Evommune downgraded to Market Perform from Outperform at William Blair

Evommune Publishes Migraine Presentation on Mrgprx2 Antagonism

Evommune Inc : RBC Cuts Target Price to $30 from $50

THOMSON REUTERS

Evommune Halts EVO756 Urticaria Trial, Pipeline Advances

Evommune Says Evo756 Phase 2b Trial in Chronic Spontaneous Urticaria Misses Primary Endpoint

Evommune - to Report Evo756 Phase 2B Atopic Dermatitis Data in Q3 2026

THOMSON REUTERS

Evommune Announces Top-line Results from Evo756 Phase 2B Trial in Moderate-to-severe Chronic Spontaneous Urticaria

THOMSON REUTERS

Evommune - Initiates Screening for Evo756 Phase 2B Migraine Trial

THOMSON REUTERS

Evommune - to Continue Evo756 Development in Atopic Dermatitis and Migraine

THOMSON REUTERS

Evommune - Evo756 Phase 2B Csu Trial Did not Meet Primary Endpoint at 12 Weeks

THOMSON REUTERS

Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)

Evommune publishes presentation on interstitial fluid proteomics in chronic urticaria patients

Evommune director David E. Cohen disposes of common shares worth $123,166.76

Evommune Chief Scientific Officer Jeegar Pravinkumar Patel disposes of common shares worth $379,631.38

Evommune President and CEO Luis C. Pena sells 16,787 shares worth $381,694.38

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/EVMN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":6.89,"timestamp":1790959612262,"preClose":7.21,"halted":0,"volume":527819,"delay":0,"changeRate":-0.044382801664355105,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Trading","change":-0.32,"latestTime":"10-02 12:46:52 EDT","open":7.18,"high":7.28,"low":6.88,"amount":3717665.679912,"amplitude":0.055479,"askPrice":6.91,"askSize":240,"bidPrice":6.9,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":7.21,"preHourTrading":{"tag":"盘前","latestPrice":7.02,"preClose":7.21,"latestTime":"09:15 EDT","volume":942,"amount":6587.562372,"timestamp":1790946940212,"change":-0.19,"changeRate":-0.026352,"amplitude":0.009709},"postHourTrading":{"tag":"盘后","latestPrice":7.2,"preClose":7.21,"latestTime":"19:40 EDT","volume":29965,"amount":215232.8508,"timestamp":1790898004365,"change":-0.01,"changeRate":-0.001387,"amplitude":0.059639},"volumeRatio":1.226489,"impliedVol":0.712,"impliedVolPercentile":0.1947},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":1.226489,"shares":36292113,"dividePrice":0,"high":7.28,"amplitude":0.055479,"preClose":7.21,"low":6.88,"week52Low":6.88,"pbRate":"0.90","psRate":"25.01","week52High":33.2,"institutionHeld":0,"latestPrice":6.89,"committee":-0.882353,"eps":-2.609,"divideRate":0,"volume":527819,"delay":0,"ttmEps":-2.609,"open":7.18,"prevYearClose":17.12,"prevWeekClose":8.49,"prevMonthClose":8.26,"prevQuarterClose":8.26,"fiveDayClose":8.49,"twentyDayClose":12,"sixtyDayClose":13.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1787803200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-10-01","current":-2.644691,"percent":1,"low":-16.229076,"twenty":-12.303359,"median":-9.479385,"eighty":-5.516493,"high":-3.16657,"avg":-9.281325,"sd":3.229597,"marketCap":299772853},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973},{"date":"2026-08-28","current":-5.16772,"twenty":-12.413708,"median":-9.712404,"eighty":-6.987812,"marketCap":489217683},{"date":"2026-09-04","current":-4.600344,"twenty":-12.384421,"median":-9.710846,"eighty":-6.276801,"marketCap":435505356},{"date":"2026-09-11","current":-4.048303,"twenty":-12.366639,"median":-9.695292,"eighty":-6.160195,"marketCap":383244713},{"date":"2026-09-18","current":-3.592102,"twenty":-12.358271,"median":-9.618094,"eighty":-5.832183,"marketCap":340057098},{"date":"2026-09-25","current":-3.373586,"twenty":-12.336306,"median":-9.537021,"eighty":-5.714629,"marketCap":319370594},{"date":"2026-10-01","current":-3.16657,"twenty":-12.303359,"median":-9.479385,"eighty":-5.516493,"marketCap":299772853}],"updateTime":1790959612669},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2647370102","title":"Evommune Inc : Leerink Partners Cuts Target Price to $28 from $52","url":"https://stock-news.laohu8.com/highlight/detail?id=2647370102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647370102?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:35","pubTimestamp":1782743711,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN4310V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647670377","title":"Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647670377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647670377?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:50","pubTimestamp":1782741008,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH) with neutral ratings, indicating that the exper...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-and-theravance-biopharma-tbph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-and-theravance-biopharma-tbph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4588","BK4585","XBI","BK4137","TBPH","BK4581","LABU","XLV","HCSG","BK4007","EVMN","LU0029874061.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372007","title":"Evommune Sinks as Skin Disease Drug Fails Mid-stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372007?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:47","pubTimestamp":1782740844,"startTime":"0","endTime":"0","summary":"BUZZ-Evommune sinks as skin disease drug fails mid-stage trial** Shares of drug developer EvommuneEVMN.Nfall 32% to over four-month low of $17.10** Co says its experimental pill, EVO756, did not reduce hive activity scores significantly better than a placebo after 12 weeks, failing to meet the main goal of a mid-stage trial** Co was testing the drug in patients with moderate-to-severe chronic spontaneous urticaria, commonly known as chronic hives, which causes recurring itchy welts on the skin that can last for months or years and significantly disrupt daily life** RBC Capital Markets analysts cut Evommune's PT to $30 from $50 and said the research firm believes \"the issue is more likely the indication rather than the drug or mechanism\"** EVO756 works by blocking the MRGPRX2 receptor on mast cells, a pathway involved in triggering inflammation and itch** The trial enrolled 160 patients who had not responded to standard antihistamines** Co says it plans to continue development of EVO756","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N43114C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377951","title":"Evommune downgraded to Market Perform from Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647377951?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:40","pubTimestamp":1782740441,"startTime":"0","endTime":"0","summary":"William Blair downgraded Evommune (EVMN) to Market Perform from Outperform without a price target after the company announced that the Phase IIb st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-downgraded-to-market-perform-from-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-downgraded-to-market-perform-from-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372957","title":"Evommune Publishes Migraine Presentation on Mrgprx2 Antagonism","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372957?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:25","pubTimestamp":1782739518,"startTime":"0","endTime":"0","summary":"Evommune publishes migraine presentation on MRGPRX2 antagonismEvommune published a medical research presentation outlining MRGPRX2 antagonism as a potential migraine approach targeting meningeal mast ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL83sMQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647937266","title":"Evommune Inc : RBC Cuts Target Price to $30 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2647937266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647937266?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:24","pubTimestamp":1782739476,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN4310OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647741253","title":"Evommune Halts EVO756 Urticaria Trial, Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2647741253","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647741253?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:59","pubTimestamp":1782737952,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ( ($EVMN) ) has shared an update. On June 29, 2026, Evommune reported top-line results from a randomized, double-blind, placebo-cont...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-halts-evo756-urticaria-trial-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-halts-evo756-urticaria-trial-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371114","title":"Evommune Says Evo756 Phase 2b Trial in Chronic Spontaneous Urticaria Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371114","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371114?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736237,"startTime":"0","endTime":"0","summary":"Evommune says EVO756 Phase 2b trial in chronic spontaneous urticaria misses primary endpointEvommune reported top-line Phase 2b results for oral EVO756 in chronic spontaneous urticaria.The trial misse","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9jF3qF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647937110","title":"Evommune - to Report Evo756 Phase 2B Atopic Dermatitis Data in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647937110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647937110?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371940","title":"Evommune Announces Top-line Results from Evo756 Phase 2B Trial in Moderate-to-severe Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371940?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371174","title":"Evommune - Initiates Screening for Evo756 Phase 2B Migraine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371174?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371173","title":"Evommune - to Continue Evo756 Development in Atopic Dermatitis and Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371173?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647160371","title":"Evommune - Evo756 Phase 2B Csu Trial Did not Meet Primary Endpoint at 12 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2647160371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647160371?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646842938","title":"Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2646842938","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646842938?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:00","pubTimestamp":1782345623,"startTime":"0","endTime":"0","summary":"Evommune CEO Luis C. Pena sells 7,438 common shares worth $168,904.98Evommune President, CEO, director Luis C. Pena sold 7,438 common shares on June 22, 2026.Sale priced at a weighted average of USD 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL1C0T6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645038980","title":"Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2645038980","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645038980?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:55","pubTimestamp":1782165309,"startTime":"0","endTime":"0","summary":"Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-deal-gives-positive-readthrough-to-evommune-pipeline-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-deal-gives-positive-readthrough-to-evommune-pipeline-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","IE0004445239.USD","LU0256863811.USD","IE00BJT1NW94.SGD","BK4581","LU1989772923.USD","BK4534","IE0002141913.USD","LU1496350171.SGD","LU2129689431.USD","LU0661504455.SGD","LU0912757837.SGD","IE000BZT7R73.USD","ABBV","LU1244550577.SGD","LU0859254822.USD","LU1585245621.USD","LU1267930490.SGD","LU0211328371.USD","SG9999011175.SGD","LU1291159041.SGD","EVMN","LU0689626769.HKD","LU0057025933.USD","LU1989772840.SGD","LU0861579265.USD","LU1934455277.USD","LU1839511570.USD","LU2237443465.HKD","LU1732800096.USD","IE0009355771.USD","LU0472753341.HKD","LU0820561818.USD","LU0965509010.AUD","LU1551013425.SGD","LU2089283258.USD","LU1989771016.USD","LU2347655156.SGD","LU2357627491.SGD","LU0211327993.USD","IE00BSNM7G36.USD","APGE","LU0820561909.HKD","LU0203345920.USD","LU0203347892.USD","BK4139","LU1934455194.USD","LU2023251221.USD","LU0098860793.USD","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026057","title":"Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642026057?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:31","pubTimestamp":1781263876,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (AL...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-immunome-imnm-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-immunome-imnm-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU2265009873.SGD","BK4563","LU0128526141.USD","IMNM","LU0029874061.USD","BK4139","LU1804176565.USD","BK4137","EVMN","BK4534","ALC","BK4581","BK4585","HCSG","XLV","BK4588","LABU","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642535478","title":"Evommune publishes presentation on interstitial fluid proteomics in chronic urticaria patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642535478","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642535478?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:23","pubTimestamp":1781112223,"startTime":"0","endTime":"0","summary":"Evommune published a medical research presentation on proteomic profiling of dermal interstitial fluid in chronic inducible urticaria and chronic spontaneous urticaria.Lesional samples showed higher mast cell activation markers versus non-lesional skin, supporting mast cell involvement in both conditions.The analysis found enrichment of endogenous MRGPRX2 ligands in lesions, pointing to a shared MRGPRX2-driven disease mechanism.Proteomic signatures also indicated elevated inflammatory cytokines and chemokines in lesional skin, consistent across both patient groups.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL3p2TCy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640180426","title":"Evommune director David E. Cohen disposes of common shares worth $123,166.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2640180426","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640180426?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:03","pubTimestamp":1780531421,"startTime":"0","endTime":"0","summary":"Evommune director David E. Cohen sold 6,056 common shares on June 2, 2026 at weighted-average prices of USD 20.21 and USD 21.38.Holdings fell to 17,609 common shares following the sales.Cohen also received stock options for 15,673 shares at an exercise price of USD 19.82, expiring June 1, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLbPnQqX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640429180","title":"Evommune Chief Scientific Officer Jeegar Pravinkumar Patel disposes of common shares worth $379,631.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2640429180","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640429180?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:03","pubTimestamp":1780531399,"startTime":"0","endTime":"0","summary":"Evommune Chief Scientific Officer Jeegar Pravinkumar Patel sold 16,687 common shares on June 1 at USD 22.74.He exercised employee stock options for 13,512 shares at USD 3.84 on the same day.He held 46,403 common shares following the transactions.He also held 29,330 employee stock options after the exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL5dPXlG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640718049","title":"Evommune President and CEO Luis C. Pena sells 16,787 shares worth $381,694.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2640718049","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640718049?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:02","pubTimestamp":1780531365,"startTime":"0","endTime":"0","summary":"Shares sold at a weighted average price of $22.74.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7m24PZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune President and CEO Luis C. Pena sells 16,787 shares worth $381,694.38","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":106,"code":"91000000","status":"200"}]}}